Abstract The National Institutes of Health, Centers for Disease Control and Prevention, and
World Health Organization jointly sponsored a workshop on protective and disease …

Respiratory syncytial virus (RSV) is an important cause of respiratory illness in children and
adults. Development of an effective vaccine against RSV faces three major challenges. First …

Respiratory syncytial virus (RSV) remains a significant cause of morbidity and mortality in
infants and young children, immunocompromised patients and the elderly. Despite the high …

Respiratory syncytial virus (RSV) is a serious pathogen causing significant mortality and
morbidity, especially in premature infants and infants with chronic lung disease or significant …

The respiratory syncytial virus (RSV) is the major cause of lower respiratory tract illness (LRI)
in infants worldwide. Also persons with heart/lung disease or an immunodeficiency disorder …

Respiratory syncytial virus (RSV) is a globally prevalent cause of lower respiratory infection
in neonates and infants. Despite its disease burden, a safe and effective RSV vaccine has …

Summary 2017 will mark the 60 th anniversary since the first isolation of RSV in children. In
spite of concerted efforts over all these years, the goal of developing an effective vaccine …

Since the respiratory syncytial virus (RSV) was initially isolated from chimpanzee in 1956, it
has been identified as an important cause of lower respiratory tract disease in infants …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

Respiratory syncytial virus (RSV) is the most important causative agent of respiratory tract
infections. Young children with chronic lung or congenital heart disease are at increased risk …